CN105209064A - 使用抗il-23抗体治疗银屑病的方法 - Google Patents

使用抗il-23抗体治疗银屑病的方法 Download PDF

Info

Publication number
CN105209064A
CN105209064A CN201480015797.0A CN201480015797A CN105209064A CN 105209064 A CN105209064 A CN 105209064A CN 201480015797 A CN201480015797 A CN 201480015797A CN 105209064 A CN105209064 A CN 105209064A
Authority
CN
China
Prior art keywords
antibody
amg139
antibodies
months
amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480015797.0A
Other languages
English (en)
Chinese (zh)
Inventor
J.P.吉布斯
W.楚吉
W-J.潘
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50336511&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN105209064(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CN105209064A publication Critical patent/CN105209064A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
CN201480015797.0A 2013-03-15 2014-02-25 使用抗il-23抗体治疗银屑病的方法 Pending CN105209064A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361789777P 2013-03-15 2013-03-15
US61/789777 2013-03-15
PCT/US2014/018293 WO2014149425A1 (en) 2013-03-15 2014-02-25 Methods for treating psoriasis using an anti-il-23 antibody

Publications (1)

Publication Number Publication Date
CN105209064A true CN105209064A (zh) 2015-12-30

Family

ID=50336511

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480015797.0A Pending CN105209064A (zh) 2013-03-15 2014-02-25 使用抗il-23抗体治疗银屑病的方法

Country Status (17)

Country Link
US (3) US20160060337A1 (enExample)
EP (2) EP2968488A1 (enExample)
JP (4) JP2016517408A (enExample)
KR (1) KR20150128858A (enExample)
CN (1) CN105209064A (enExample)
AP (1) AP2015008803A0 (enExample)
AU (3) AU2014238148A1 (enExample)
CA (1) CA2906382A1 (enExample)
CL (1) CL2015002723A1 (enExample)
CR (1) CR20150572A (enExample)
EA (1) EA201591581A1 (enExample)
HK (1) HK1219425A1 (enExample)
IL (2) IL241342A0 (enExample)
PH (2) PH12015502129A1 (enExample)
SG (2) SG10201804954UA (enExample)
TN (1) TN2015000403A1 (enExample)
WO (1) WO2014149425A1 (enExample)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071653A (zh) * 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
CN113853385A (zh) * 2019-03-18 2021-12-28 詹森生物科技公司 用抗il12/il23抗体治疗儿科受试者的银屑病的方法

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2635601B1 (en) 2010-11-04 2016-07-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies
WO2013165791A1 (en) 2012-05-03 2013-11-07 Boehringer Ingelheim International Gmbh Anti-il-23p19 antibodies
EP3172339A1 (en) 2014-07-24 2017-05-31 Boehringer Ingelheim International GmbH Biomarkers useful in the treatment of il-23a related diseases
US10059763B2 (en) 2014-09-03 2018-08-28 Boehringer Ingelheim International Gmbh Compound targeting IL-23A and TNF-alpha and uses thereof
IL307578A (en) * 2015-02-04 2023-12-01 Boehringer Ingelheim Int Methods of treating inflammatory diseases
AU2017250583A1 (en) * 2016-04-15 2018-08-16 Boehringer Ingelheim International Gmbh Methods of treating inflammatory diseases
JP7634474B2 (ja) * 2018-07-18 2025-02-21 ヤンセン バイオテツク，インコーポレーテツド 抗ｉｌ２３特異的抗体で治療した後の持続応答予測因子
KR20210091209A (ko) * 2018-11-05 2021-07-21 머크 샤프 앤드 돔 코포레이션 암의 치료를 위한 항-tigit 항체의 투여 요법

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101663320A (zh) * 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
CN102037011A (zh) * 2008-03-18 2011-04-27 雅培制药有限公司 用于治疗银屑病的方法
WO2012048134A2 (en) * 2010-10-06 2012-04-12 Abbott Laboratories Methods for treating psoriasis
CN102741285A (zh) * 2009-10-26 2012-10-17 安姆根有限公司 人il-23抗原结合蛋白

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CO4810232A1 (es) 1997-07-25 1999-06-30 Schering Corp Citoquinas de mamiferos y sus secuencias codificadoras
ES2410406T3 (es) 2005-06-30 2013-07-01 Janssen Biotech, Inc. Anticuerpos anti-IL-23, composiciones, procedimientos y usos
EP1937721B1 (en) 2005-08-25 2010-07-28 Eli Lilly And Company Anti-il-23 antibodies
US20070050011A1 (en) 2005-08-26 2007-03-01 Medlogics Device Corporation Lumen-supporting stents and methods for creating lumen-supporting stents with various open/closed designs
HUE032131T2 (en) 2005-08-31 2017-09-28 Merck Sharp & Dohme Constructed anti-IL-23 antibodies
AU2006330410A1 (en) * 2005-12-28 2007-07-05 Centocor, Inc. Markers and methods for assessing and treating psoriasis and related disorders
EP3219328B1 (en) 2005-12-29 2020-06-17 Janssen Biotech, Inc. Human anti-il-23 antibodies, compositions, method and uses
AU2007260787A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc IL-17 and IL-23 antagonists and methods of using the same
ATE554791T1 (de) 2007-02-23 2012-05-15 Schering Corp Gentechnisch hergestellte anti-il-23p19- antikörper
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
WO2009082624A2 (en) 2007-12-10 2009-07-02 Zymogenetics, Inc. Antagonists of il-17a, il-17f, and il-23 and methods of using the same
US8557239B2 (en) * 2009-09-14 2013-10-15 Abbvie Inc. Methods for treating psoriasis using antibodies that bind to the P40 subunit of IL-12 and/or IL-23
WO2010002776A2 (en) 2008-06-30 2010-01-07 Black & Decker Inc. Cord protector for power tools
WO2010027766A1 (en) 2008-08-27 2010-03-11 Schering Corporation Lyophilized formulatons of engineered anti-il-23p19 antibodies
WO2010115786A1 (en) 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
WO2010142534A1 (en) 2009-05-27 2010-12-16 Ablynx Nv Biparatopic protein constructs directed against il-23
WO2011088120A1 (en) 2010-01-15 2011-07-21 Amgen Inc. Antibody formulation and therapeutic regimens
US9127057B2 (en) 2010-07-20 2015-09-08 Teva Pharmaceuticals Ausralia Pty Ltd Anti-IL-23 heterodimer specific antibodies
CN103154031A (zh) * 2010-10-08 2013-06-12 诺华有限公司 利用il-17拮抗剂治疗牛皮癣的方法
EP2635601B1 (en) 2010-11-04 2016-07-20 Boehringer Ingelheim International GmbH Anti-il-23 antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101663320A (zh) * 2007-02-23 2010-03-03 先灵公司 工程改造的抗IL-23p19抗体
CN102037011A (zh) * 2008-03-18 2011-04-27 雅培制药有限公司 用于治疗银屑病的方法
CN102741285A (zh) * 2009-10-26 2012-10-17 安姆根有限公司 人il-23抗原结合蛋白
WO2012048134A2 (en) * 2010-10-06 2012-04-12 Abbott Laboratories Methods for treating psoriasis

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109071653A (zh) * 2016-03-29 2018-12-21 詹森生物科技公司 用增加的抗-il12和/或-23抗体给药间隔治疗牛皮癣
CN113853385A (zh) * 2019-03-18 2021-12-28 詹森生物科技公司 用抗il12/il23抗体治疗儿科受试者的银屑病的方法

Also Published As

Publication number Publication date
CR20150572A (es) 2016-04-25
WO2014149425A1 (en) 2014-09-25
CL2015002723A1 (es) 2016-03-28
EP3689369A1 (en) 2020-08-05
US20220135668A1 (en) 2022-05-05
PH12019502700A1 (en) 2020-12-07
TN2015000403A1 (en) 2017-01-03
AU2014238148A1 (en) 2015-10-08
EA201591581A1 (ru) 2016-01-29
EP2968488A1 (en) 2016-01-20
SG10201804954UA (en) 2018-07-30
US20200277368A1 (en) 2020-09-03
JP2016517408A (ja) 2016-06-16
JP2021102644A (ja) 2021-07-15
SG11201507482UA (en) 2015-10-29
US20160060337A1 (en) 2016-03-03
AP2015008803A0 (en) 2015-10-31
KR20150128858A (ko) 2015-11-18
PH12015502129A1 (en) 2016-01-25
IL275093A (en) 2020-07-30
IL241342A0 (en) 2015-11-30
JP2023011815A (ja) 2023-01-24
AU2019200206A1 (en) 2019-01-31
HK1219425A1 (zh) 2017-04-07
AU2020270495A1 (en) 2020-12-17
JP2020063237A (ja) 2020-04-23
CA2906382A1 (en) 2014-09-25

Similar Documents

Publication Publication Date Title
US20220135668A1 (en) Methods for Treating Psoriasis Using an Anti-IL-23 Antibody
US20200283517A1 (en) Methods for treating chron's disease using an anti-il23 antibody
TWI548419B (zh) 利用ｉｌ－１７拮抗劑治療牛皮癬的方法
JP2024109762A (ja) Ｉｌ－１７アンタゴニストを使用して汎発性膿疱性乾癬（ｇｐｐ）を処置する方法
TW201414493A (zh) 藉由投與ｉｌ－４ｒ拮抗劑治療異位性皮膚炎的方法
TW202106712A (zh) 類風溼性關節炎之診斷及治療方法
US20210277105A1 (en) Treating ulcerative colitis with brazikumab
HK40034615A (en) Methods for treating psoriasis using an anti-il-23 antibody
HK40034614A (en) Methods for treating crohn’s disease using an anti-il23 antibody

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1219425

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20151230

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1219425

Country of ref document: HK